MedTrace Logo

Antiplatelet Therapy for Silent Brain Infarction

NCT03318744 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3400

Last updated 2017-10-25

No results posted yet for this study

Summary

Silent brain infarction (SBI) or incidental infarct is common. Recent studies revealed individuals with SBI have an increased risk of future stroke. Even though the 2014 AHA/ASA recommendation for ischemic stroke and transient ischemic attack considered SBI as an entry point for secondary prevention, convincing evidence with regard to the preventive efficacy of antiplatelet therapy against incident stroke in SBI is scant. Investigators examine if antiplatelet therapy can effectively decrease the incidence of future stroke in SBI individuals.

Conditions

  • Brain Infarction

Interventions

DRUG

Aspirin

Aspirin is one of the most widely used antithrombotic agents to prevent recurrent ischemic stroke for patients with prior symptomatic ischemic stroke.

DRUG

Placebo Oral Tablet

Placebo resembling aspirin tablet will be be given to participants in control arm.

Sponsors & Collaborators

  • First People's Hospital of Shenyang

    lead OTHER

Principal Investigators

  • Yi Sui, MD PhD · First People's Hospital of Shenyang

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-31
Primary Completion
2021-07-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03318744 on ClinicalTrials.gov